Araclon Biotech Selects MedAvante Virgil Platform for Phase 2 Alzheimer's Trial

Thursday, March 30, 2017 General News
Email Print This Page Comment
Font : A-A+

Shared Goal Is Improving Signal Detection and Data Quality through Standardization

ZARAGOZA, Spain and HAMILTON, N.J., March 30, 2017

/PRNewswire/ -- Araclon Biotech, a Grifols company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, and MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, today announced that Araclon Biotech has selected MedAvante's groundbreaking VirgilŪ Investigative Study Platform for its upcoming Phase 2 trial in prodromal or very mild Alzheimer's disease (AD).

The Araclon study will investigate the safety, tolerability and immune response of ABvac40, a treatment based on an innovative, specific active immunotherapy against the beta-amyloid 40 protein designed to combat Alzheimer's disease at its initial stage.

MedAvante will provide the Virgil electronic clinical outcome assessment (eCOA) platform for all clinician-rated outcome assessments to maximize outcome data quality and increase operational efficiency. The Virgil platform, consisting of a tablet device for digital capture with access to the industry's largest library of electronic rating scales translated to dozens of languages and a tightly integrated web portal for real time data analysis, is currently being used in trials at more than 900 sites in 30 countries.

In addition, MedAvante training will help to standardize the multinational rater cohort, and MedAvante clinicians will perform diagnostic verification and Central Review of the key screening assessments to ensure the quality of administration.

"The ability to detect a sufficient signal to demonstrate efficacy in this type of trial is put at risk by several factors, including the complexity of clinical outcome assessment data, the potential to include ineligible subjects or inflate baseline scoring, and the variability among raters with diverse backgrounds collecting the outcome measures," said Christopher Randolph, PhD, ABPP-CN, Chief Scientific Officer at MedAvante. "For Araclon Biotech, the Virgil platform and MedAvante clinical services address all these risks."

"Araclon Biotech is very pleased to enlist MedAvante's clinical experience and technology leadership for our Phase 2 trial to evaluate the efficacy of the ABvac40 compound," said Manuel Sarasa, Scientific Director of Araclon Biotech. "In the Phase 1 study, the vaccine demonstrated a good safety and tolerability profile and produced an immune response in a high percentage of patients but does not assess its effectiveness as a treatment."

"Anticipating our next study, we looked at all options and determined MedAvante brings not only the  most eCOA experience, but can also offer a high degree of clinical expertise on study team and the ability to scale their services to a trial the size of ours," he said. "The Virgil eCOA platform will ensure that we collect high quality outcome data and MedAvante's clinical cohort will help us to be certain that we're enrolling the right patients and screening them accurately."

MedAvante pioneered electronic source (eSource) data capture in 2009 for use by its own clinicians and since then has garnered more eSource experience than anyone else in the industry – more than 630,000 assessments and eSource data accepted by both the FDA and the EMA in successful regulatory submissions.

About Araclon Biotech, a Grifols company

Araclon Biotech specializes in researching and developing therapies and methods for diagnosing Alzheimer's disease (AD) and other neurodegenerative diseases. This Grifols' company is currently focused on two lines of research: the early diagnosis of AD, through detection of beta-amyloid 40 and 42 peptides in blood, and treatment of the disease by immunotherapy (vaccine).

About MedAvante

MedAvante is the global clinical data services company dedicated to maximizing signal detection in clinical trials. Founded in 2002, MedAvante pioneered Central Ratings, a groundbreaking clinical trial methodology. This heritage of clinical expertise, coupled with technical innovation and operational skills, enabled MedAvante to develop the electronic source (eSource) platform, Virgil, the first such technology to replace costly and error-prone paper rating scales with real-time digital collection and cloud management of source data. Designed by clinicians for clinicians, Virgil offers built-in clinical guidance to ensure accurate, standardized assessments. MedAvante helps bring better drug therapies to market through smarter, faster clinical trials. Based in Hamilton, NJ with operations teams in the US, Germany, Russia and Japan, MedAvante delivers services for clinical trials in more than 40 countries worldwide. For more information, please visit www.medavante.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/araclon-biotech-selects-medavante-virgil-platform-for-phase-2-alzheimers-trial-300431823.html

SOURCE MedAvante, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook